A European institution built from national expertise
Europe should be proud of the European Medicines Agency and the regulatory network around it because they turned national scientific capacity into a shared public institution. A medicine developer no longer needs a separate top-level scientific verdict from every member state for products in the centralised route. Experts from across Europe assess common evidence, the European Commission can issue one legally binding authorisation, and the same network keeps watching safety long after a medicine reaches patients.
The achievement is not one building in Amsterdam. EMA sits at the centre of a partnership connecting the European Commission and more than 50 national competent authorities for human and veterinary medicines across the EU and European Economic Area. Those authorities make thousands of scientists available to committees, working parties and assessment teams. EMA's current network page describes about 4,000 experts, while the national authorities retain essential inspection, authorisation, supervision and enforcement work.
Europe created EMA in 1995 to harmonise the work of existing national regulators and manage a centralised authorisation procedure. The model respected capability already present in countries instead of pretending expertise began in a new agency. Rapporteurs and co-rapporteurs lead assessments, multinational teams can add specialised knowledge from other states, scientific committees debate the evidence, and EMA coordinates the process and publishes the result.
That division of roles is worth stating accurately. EMA evaluates centralised applications and its Committee for Medicinal Products for Human Use, the CHMP, adopts a scientific opinion. The European Commission is the body that takes the legally binding marketing-authorisation decision. National authorities authorise many medicines outside the centralised procedure and cooperate through mutual-recognition and decentralised routes. Pricing, reimbursement, procurement and clinical use remain largely national decisions.
One central assessment and a Union-wide decision
For medicines within the centralised route, one application can lead to one evaluation and one authorisation valid across the EU, with the EEA countries Iceland, Liechtenstein and Norway participating through the wider system. Biotechnology products, advanced therapies and medicines for major disease areas are among those required to use this route; other eligible innovative products can use it too. The same scientific dossier is not re-litigated from zero in every national capital.
A common authorisation does not mean automatic availability in every pharmacy. A company still decides where and when to launch, health systems negotiate price and reimbursement, supply can fail, and national clinical guidance may differ. EMA itself warns that a centrally authorised medicine may not be available in every member state. The European achievement is a common standard and legal gateway, not a promise that every patient receives every treatment at the same time.
The scientific process is deliberately demanding. EMA validates the application, assessment teams review quality, non-clinical and clinical evidence, committees ask questions, and the company may stop the clock to respond. The standard central assessment has a maximum of 210 active days, excluding those pauses. Accelerated assessment can reduce the active timetable to 150 days for a medicine of major public-health interest, but the evidence requirements do not disappear.
Evidence, negative opinions and patient participation
In 2025 the CHMP recommended 104 human medicines for marketing authorisation, including 38 with a new active substance. It adopted seven negative opinions, and applicants withdrew 20 applications before an opinion, usually because the submitted data could not support authorisation. Those outcomes matter: a serious regulator is valuable not only when it opens a door but when it requires more evidence, limits an indication or refuses to recommend approval.
European regulation also begins before the final application. Developers can seek scientific advice on study design, endpoints and evidence generation; rare-disease developers can obtain protocol assistance; the PRIME scheme supports promising medicines addressing unmet need. EMA reported 647 scientific-advice requests in 2025, including 133 protocol-assistance requests. Early dialogue can make research more useful without converting advice into a promise of approval.
Patients and healthcare professionals are part of the governance rather than only the audience for the final decision. Representatives participate in most EMA scientific committees, and the orphan-medicines committee was the first to include patients formally in 2000. Their experience does not replace controlled evidence, toxicology, statistics or clinical expertise. It adds knowledge about disease burden, acceptable uncertainty, practical treatment and information needs to a multidisciplinary judgment.
Public assessment reports and transparent reasoning
Transparency is another European public asset. For every centrally authorised medicine, EMA publishes a European public assessment report, or EPAR, explaining how the evidence was assessed. The package includes a public-friendly overview, scientific assessment material and the approved product information. Summaries and product information are published in all official EU languages, allowing clinicians, patients, researchers, journalists and other regulators to inspect more than a press release.
The public record includes negative outcomes too. EMA publishes information on refused applications and on withdrawals, committee agendas and minutes, safety recommendations, conflicts-of-interest declarations and many regulatory documents. Commercially confidential information and personal data still require protection, and publication timing is not perfect. Yet the principle is powerful: a continental decision about a medicine should leave a reviewable evidence trail.
Safety monitoring through EudraVigilance
Authorisation is the beginning of a medicine's monitored life, not the end of scrutiny. New adverse reactions, interactions, manufacturing issues, use in wider populations and long-term outcomes can change the benefit-risk balance. EMA's Pharmacovigilance Risk Assessment Committee and national authorities review signals, periodic safety reports and risk-management measures. Recommendations can change warnings, restrict use, require studies, suspend a product or support withdrawal.
EudraVigilance gives that work a shared data backbone. Patients, professionals, companies and authorities contribute suspected adverse-reaction reports through defined routes, and EMA and national regulators analyse them for new or changed safety signals. More than 1.7 million reports entered the system in 2025; 64% originated outside the EEA. EMA reviewed 1,201 potential signals, with about 68% originating from EudraVigilance monitoring, and the PRAC assessed 60 signals.
A suspected-reaction report is not proof that a medicine caused an event. Reports can be incomplete, duplicated, affected by publicity or missing the number of people exposed. Their strength is collective detection: a pattern that one hospital or country cannot see may become visible across a much larger evidence base. Regulators then test the signal against clinical studies, literature, biological plausibility, usage data and other evidence before deciding whether action is needed.
Clinical trials and shortage coordination
Europe is also joining clinical-trial administration and transparency. The Clinical Trials Information System is now the single EU platform for trial authorisation and oversight under the Clinical Trials Regulation. EMA reported that 5,088 trials were migrated from the older system and that, since launch, CTIS had received nearly 13,000 initial applications, with more than 10,600 trials authorised by member states by the 2025 reporting point. A public portal and trial map make study information searchable beyond specialist circles.
Medicine shortages show why authorisation alone is insufficient. Factories, active ingredients, quality failures, demand shocks, commercial withdrawals, procurement choices and global logistics can leave an approved medicine unavailable. Europe has added coordination through the Single Point of Contact network, the Medicines Shortages Steering Group and the European Shortages Monitoring Platform, which became fully operational in January 2025 for shared reporting by authorities and marketing-authorisation holders.
The 2025 record gives one modest but concrete result. Six voluntary solidarity procedures were launched after countries faced critical shortages and exhausted other options; in every case at least one member state could provide support. That does not prove shortages are solved, and moving stock can shift pressure elsewhere. It shows the civic value of a system in which a national authority can ask a European network for verified help rather than negotiate alone in a crisis.
Independence, access and global supply chains
The network's scale creates responsibilities as well as strength. Regulators depend on fees and public resources, compete with industry for scientific talent, face increasingly complex cell, gene, AI-supported and personalised therapies, and must inspect global manufacturing chains. Conflicts of interest need active control. Cybersecurity and database continuity are public-health issues. Speed matters to patients, but a faster timetable cannot become permission to lower the evidential bar invisibly.
Access inequality is the hardest limitation. A shared scientific approval can coexist with different prices, reimbursement decisions, launch dates, diagnostic capacity and hospital resources. Rare-disease and advanced medicines may be authorised yet remain unreachable or unaffordable for many patients. Those gaps are not evidence that common regulation failed; they show where Europe's health cooperation remains incomplete and where joint assessment, procurement, manufacturing resilience and fair financing need further democratic work.
The network also relies on the wider world. Clinical trials, active ingredients, manufacturing sites, safety reports, scientific standards and supply chains are global. European regulators cooperate with the World Health Organization, the United States, Japan and other authorities, and many authorised medicines originate with non-European companies or research. Strategic capacity does not require pretending Europe invented every molecule. It requires the ability to assess evidence independently, enforce European standards and act when risks change.
A federal model for public health
The EMBL feature shows Europe pooling life-science research and open data; EuroHPC shows shared computing capacity; the Eurotransplant feature shows a shared allocation service matching scarce donated organs; and the EU Civil Protection Mechanism shows national capability reinforced by continental coordination. The medicines network combines these logics: distributed expertise, common data infrastructure and standing mechanisms for joint decisions under pressure.
For Federal Europa, this is a mature federal pattern. National authorities remain real and accountable; specialised expertise can sit anywhere; shared law creates a common decision; an independent coordinating agency organises evidence; the Commission takes the Union-wide legal act; public reports let citizens inspect the basis; and national health systems decide how treatment is financed and delivered. Unity increases capability without making every institution identical.
Europe has spent more than thirty years building this regulatory commons. Its value is visible in the medicines approved, but also in negative opinions, updated warnings, public assessment reports, trial transparency, shortage alerts and the quiet work of thousands of scientists who compare evidence across borders. The next test is to keep the network scientifically independent, properly resourced, technically secure, faster where possible and connected to fair access. The achievement is already profound: Europeans made medicine oversight a shared public responsibility at continental scale.